Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Timdarpacept + Azacitidine in Newly Diagnosed CMML
NCT06647862Phase 3Recruiting
- Sponsor
- ImmuneOnco
- Start
- Nov 2024
- Primary completion
- Apr 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of timdarpacept in chronic myelomonocytic leukemia (CMML), sponsored by ImmuneOnco. Started Nov 2024; status: recruiting.
02
Drugs
timdarpacept
03
Conditions
chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT06647862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06647862.